Skip to main content

Table 4 Expression of EGFR in both patient groups

From: Administration of nimotuzumab combined with cisplatin plus 5-fluorouracil as induction therapy improves treatment response and tolerance in patients with locally advanced nasopharyngeal carcinoma receiving concurrent radiochemotherapy: a multicenter randomized controlled study

EGFR expression

NPF group (%)

DPF group (%)

Total (%)

0–4%

3(5.2)

3(5.0)

6(5.1)

5–24%

10(17.2)

3(5.0)

13(17.2)

25–49%

9(15.5)

8(13.3)

17(14.4)

50–74%

26(44.8)

29(48.3)

55(46.6)

75–100%

10(17.2)

17(28.3)

27(22.9)

P

0.058

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us